Business Context and Reporting Period
Company: Medicus Pharma Ltd.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2026
Reporting Period: Event date September 11, 2026; Signed September 14, 2026.
Context: The Company is an emerging growth company incorporated in Ontario with principal executive offices in Conshohocken, Pennsylvania. Its common shares (MDCX) and warrants (MDCXW) trade on the NASDAQ Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on the termination of a specific financing agreement.
Material Changes
- Termination of Standby Equity Purchase Agreement (SEPA): On September 11, 2026, Medicus Pharma Ltd. and YA II PN, LTD. ("Yorkville") mutually terminated the SEPA dated February 10, 2025.
- Agreement Details: The terminated SEPA allowed the Company to issue and sell up to $15.0 million of common shares to Yorkville.
- Outstanding Obligations: At the time of termination, there were no outstanding borrowings, advance notices, or shares to be issued under the SEPA.
- Termination Costs: No fees are due by either party in connection with the termination.
- Continuing Arrangements: Yorkville Securities, LLC remains a sales agent under the Company's separate Equity Distribution Agreement dated December 29, 2025.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the disclosure of the agreement termination. The text does not indicate any unusual items or contingencies related to the termination other than the cessation of the specific $15.0 million facility.
Investor Verification Checklist
- Verify the status of the Equity Distribution Agreement dated December 29, 2025, to confirm Yorkville Securities, LLC's continued role as a sales agent.
- Confirm that no other standby facilities or credit lines were active or terminated concurrently with this SEPA.
- Review recent trading volumes and liquidity for MDCX and MDCXW to assess market reaction to the termination.
- Check subsequent filings for any new financing arrangements intended to replace the terminated $15.0 million SEPA capacity.